Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neo-Adjuvant Endocrine Therapy in Post-Menopausal Hormone Receptor Positive HER 2 Neu Negative Node Positive Early-Stage Breast Cancer Patients With One Year of Letrozole.

NCT07394946 is registered in ClinicalTrials.gov with Cancer Care Hospital & Research Centre Foundation, Lahore as lead sponsor.

NCT NCT07394946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07394946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neo-Adjuvant Endocrine Therapy in Post-Menopausal Hormone Receptor Positive HER 2 Neu Negative Node Positive Early-Stage Breast Cancer Patients With One Year of Letrozole.
Lead sponsor
Cancer Care Hospital & Research Centre Foundation, Lahore
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
July 31, 2029
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor-positive, her2-negative, node positive breast cancer